Showing 2601-2610 of 2839 results for "".
- ARTAS iX: Real-World Evaluation Study Shows Benefithttps://modernaesthetics.com/news/artas-ix-real-world-evaluation-study-shows-benefit/2472009/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study of The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implan
- Galderma Announces the Start of Six New Aesthetic Studieshttps://modernaesthetics.com/news/galderma-announces-the-start-of-six-new-aesthetic-studies/2472014/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://modernaesthetics.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2472023/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- ASPS Members Identify Key Plastic Surgery Trendshttps://modernaesthetics.com/news/asps-members-identify-key-plastic-surgery-trends/2472027/Breast augmentation, tummy tucks and liposuction will be the three most popular plastic surgery procedures in 2019, plastic surgeons predict. With regard to minimally invasive procedures, Botox still leads the way as the most anticipated request, followed by fillers, chemical peels, laser
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- Allergan Acquires Bonti for $195Mhttps://modernaesthetics.com/news/allergan-acquires-bonti-for-195m/2472036/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the
- Thermi Debuts Arvati Platformhttps://modernaesthetics.com/news/themi-debuts-arvati-platform/2472041/Thermi, an Almirall company, is launching Arvati, a next-generation 510K US Food and Drug Administration-cleared, true temperature-controlled radiofrequen
- New Guidelines Seek to Rein in Inappropriate Teen Plastic Surgerieshttps://modernaesthetics.com/news/new-guidelines-seek-to-rein-in-inappropriate-teen-plastic-surgeries/2472045/New teen plastic surgery guidelines call for age consideration, parental consent and other measures to improve upon the safety of these procedures. The guidelines are published in the September issue of Plastic and Reconstr
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita